Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Nov;36(11):2418–2422. doi: 10.1128/aac.36.11.2418

Penetration of zidovudine and 3'-fluoro-3'-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: relation to antiviral action.

E Ljungdahl-Ståhle 1, E Guzenda 1, D Böttiger 1, B Wahren 1, B Oberg 1, L Ståhle 1
PMCID: PMC284346  PMID: 1489185

Abstract

Cynomolgus monkeys had microdialysis probes implanted under ketamine anesthesia into peripheral veins, thigh muscles, and the brain in order to sample the extracellular fluid for the concentrations of unbound nucleoside analogs. A dose of 25 mg of zidovudine or 3'-fluoro-3'-deoxythymidine (FLT) per kg was administered subcutaneously to each of three animals. Relatively high antiviral concentrations of FLT and zidovudine were present in peripheral tissues and in the brain. It was found that the concentration of zidovudine in the brain was approximately one-third of that in muscle and veins; the same relation was observed for FLT. The in vivo unbound concentrations of both drugs in the brain, muscle, and venous blood exceeded those reported to inhibit human immunodeficiency virus replication in vitro. In addition, in a correlative study we found that the appearance of p24 antigen in sera of monkeys infected with simian immunodeficiency virus was significantly delayed by both compounds (15 mg/kg three times daily for 9 days after infection). Thus, we have shown that the extracellular concentrations of unbound FLT and zidovudine in the brain and peripheral tissues attained with in vivo antiviral doses exceed in vitro antiviral concentrations.

Full text

PDF
2418

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bazin H., Chattopadhyaya J., Datema R., Ericson A. C., Gilljam G., Johansson N. G., Hansen J., Koshida R., Moelling K., Oberg B. An analysis of the inhibition of replication of HIV and MuLV by some 3'-blocked pyrimidine analogs. Biochem Pharmacol. 1989 Jan 1;38(1):109–119. doi: 10.1016/0006-2952(89)90157-3. [DOI] [PubMed] [Google Scholar]
  2. Collins J. M., Klecker R. W., Jr, Kelley J. A., Roth J. S., McCully C. L., Balis F. M., Poplack D. G. Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid. J Pharmacol Exp Ther. 1988 May;245(2):466–470. [PubMed] [Google Scholar]
  3. De Clercq E. Targets and strategies for the antiviral chemotherapy of AIDS. Trends Pharmacol Sci. 1990 May;11(5):198–205. doi: 10.1016/0165-6147(90)90115-o. [DOI] [PubMed] [Google Scholar]
  4. Fultz P. N., McClure H. M., Anderson D. C., Swenson R. B., Anand R., Srinivasan A. Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci U S A. 1986 Jul;83(14):5286–5290. doi: 10.1073/pnas.83.14.5286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Galinsky R. E., Hoesterey B. L., Anderson B. D. Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection. Life Sci. 1990;47(9):781–788. doi: 10.1016/0024-3205(90)90550-b. [DOI] [PubMed] [Google Scholar]
  6. Haseltine W. A. Development of antiviral drugs for the treatment of AIDS: strategies and prospects. J Acquir Immune Defic Syndr. 1989;2(4):311–334. [PubMed] [Google Scholar]
  7. Klecker R. W., Jr, Collins J. M., Yarchoan R., Thomas R., Jenkins J. F., Broder S., Myers C. E. Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987 Apr;41(4):407–412. doi: 10.1038/clpt.1987.49. [DOI] [PubMed] [Google Scholar]
  8. Koshida R., Cox S., Harmenberg J., Gilljam G., Wahren B. Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1989 Dec;33(12):2083–2088. doi: 10.1128/aac.33.12.2083. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ljungdahl-Ståhle E., Trojnar J., Oberg B., Wahren B. Early appearance of simian immunodeficiency virus (SIV) antigen and antibodies as variables in evaluating antiviral drugs in macaques. J Virol Methods. 1992 Apr;37(1):43–53. doi: 10.1016/0166-0934(92)90019-a. [DOI] [PubMed] [Google Scholar]
  10. Lundgren B., Böttiger D., Ljungdahl-Ståhle E., Norrby E., Ståhle L., Wahren B., Oberg B. Antiviral effects of 3'-fluorothymidine and 3'-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr. 1991;4(5):489–498. [PubMed] [Google Scholar]
  11. Mitsuya H., Weinhold K. J., Furman P. A., St Clair M. H., Lehrman S. N., Gallo R. C., Bolognesi D., Barry D. W., Broder S. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096–7100. doi: 10.1073/pnas.82.20.7096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mitsuya H., Yarchoan R., Broder S. Molecular targets for AIDS therapy. Science. 1990 Sep 28;249(4976):1533–1544. doi: 10.1126/science.1699273. [DOI] [PubMed] [Google Scholar]
  13. Putkonen P., Böttiger B., Warstedt K., Thorstensson R., Albert J., Biberfeld G. Experimental infection of cynomolgus monkeys (Macaca fascicularis) with HIV-2. J Acquir Immune Defic Syndr. 1989;2(4):366–373. [PubMed] [Google Scholar]
  14. Sandström E. Antiviral therapy in human immunodeficiency virus infection. Drugs. 1989 Sep;38(3):417–450. doi: 10.2165/00003495-198938030-00005. [DOI] [PubMed] [Google Scholar]
  15. Ståhle L. Pharmacokinetic estimations from microdialysis data. Eur J Clin Pharmacol. 1992;43(3):289–294. doi: 10.1007/BF02333025. [DOI] [PubMed] [Google Scholar]
  16. Terasaki T., Pardridge W. M. Restricted transport of 3'-azido-3'-deoxythymidine and dideoxynucleosides through the blood-brain barrier. J Infect Dis. 1988 Sep;158(3):630–632. doi: 10.1093/infdis/158.3.630. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES